Safety and Synovial Inflammatory Response After Intra-articular Injection of Botulinum Toxin Type A in Healthy Horses

•There is a lack of information on the safety of botulinum toxin type A (BoNT-A) for intra-articular use in horses.•Intra-articular injection of 50 U of BoNT-A did not produce systemic effects of botulism.•Lameness was not observed in BoNT-A treated joints.•Inflammatory response on BoNT-A-treated jo...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of equine veterinary science Vol. 110; p. 103865
Main Authors:	Beck, Antônio Alcemar, Paz, Letícia Bisso, Frank, Maria Inês, Engelmann, Ana Martiele, Krause, Alexandre, Côrte, Flávio Desessards De La
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-03-2022
Subjects:	Animals Arthralgia - drug therapy Arthralgia - veterinary Botulinum toxin Botulinum Toxins, Type A - adverse effects Horse Horse Diseases - drug therapy Horses Injections, Intra-Articular - veterinary Intra-articular therapy Joint pain Osteoarthritis Synovial Fluid Intra-articular therapy Joint pain Osteoarthritis Botulinum toxin Horse
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•There is a lack of information on the safety of botulinum toxin type A (BoNT-A) for intra-articular use in horses.•Intra-articular injection of 50 U of BoNT-A did not produce systemic effects of botulism.•Lameness was not observed in BoNT-A treated joints.•Inflammatory response on BoNT-A-treated joints was similar to those elicited by placebo. Botulinum toxin type A (BoNT-A) is a promising alternative for patients suffering from chronic joint pain. The aim of this study was to investigate whether a single injection of BoNT-A would produce adverse effects on clinical parameters and synovial parameters as well as lameness. One randomly selected radiocarpal joint was treated with 50 U of BoNT-A in eight horses, and the contralateral joint received saline solution. All horses received injections at day 0 and were re-evaluated twice daily for 7 days for heart rate (HR), respiratory rate (RR), rectal temperature (RT), mucous membrane color, capillary refill time, intestinal motility, appetite, water intake, defecation, urination, and attitude. At these same time points, joint pain and circumference were assessed. Objective lameness evaluations were performed once daily for 7 days and synovial fluid samples were collected at baseline, post-injection hour (PIH) 24 and PIH 168 and evaluated for synovial fluid parameters. HR and RT remained clinically unaltered, despite oscillations over time (P = .001). The remaining clinical parameters were unaltered by treatment or time (P > .05). Joint pain was not elicited by flexion and palpation in both limbs as well as carpal circumference was not altered (P = .88). Lameness was observed only on saline limbs. Cellular parameters evaluated in synovial fluid samples from both carpi had significantly increased from baseline to PIH 24, decreasing at PIH 168 (P < .05). It was concluded that the injection of 50 U BoNT-A is suggested to be a safe therapy for intra-articular use in horses and must be verified by further investigation.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0737-0806 1542-7412
DOI:	10.1016/j.jevs.2022.103865